Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?Zacks Investment Research · 1 day ago
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial UpdatesGuruFocus · 2 days ago
Biogen Q3 Earnings Preview: Grounds For Optimism, But Disappointment The NormSeeking Alpha · 3 days ago
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research · 3 days ago
A Look at Biogen Inc (BIIB) After 4.1% Gain -- GF Value $202.16 vs Price $243.10GuruFocus · 4 days ago
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch NowZacks Investment Research · 4 days agoBiogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 29, 2026 | $2.94 | $3.60 | Beat |
| Apr 29, 2026 | $3.05 | $3.57 | Beat |
| Feb 6, 2026 | $1.63 | $1.99 | Beat |
| Oct 30, 2025 | $3.88 | $4.81 | Beat |
| Jul 31, 2025 | $3.90 | $5.47 | Beat |
| May 1, 2025 | $2.90 | $3.02 | Beat |